<DOC>
	<DOC>NCT01644734</DOC>
	<brief_summary>To evaluate the early (3-month) impact of the long-acting anticholinergic Spiriva HH maintenance treatment on the COPD symptoms using the novel COPD Assessment test (CAT) in the real life setting of COPD patients, previously treated with short-acting bronchodilator on regular or as-needed basis.</brief_summary>
	<brief_title>Assessment of Health-status of Patients With Chronic Obstructive Pulmonary Disease (COPD) on Maintenance Therapy With Spiriva HH Measured by COPD Assessment Test (CAT) Test</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<criteria>Inclusion criteria: Male and female ambulatory outpatients being seen in a participating physicians office for routine care, Patients with a clinical diagnosis of COPD (all stages according to Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines 2010) being treated with longacting anticholinergic (Tiotropium, Spiriva® HandiHaler® ) as maintenance therapy within the product label and a maximum of the last 4 weeks (0.28. days before Visit 1), Patients previously treated with shortacting bronchodilators on regular or asneeded basis for at least 3 months before change to longacting anticholinergic treatment, Patient fluent in language of questionnaire and having the cognitive and functional abilities required to fill in the questionnaire alone. Exclusion criteria: Uncooperative patients as judged by the physician, Patients with any conditions excluded as per Country specific package insert, Patients currently enrolled in any clinical trial, Patients with COPD exacerbation or any acute disease in the last 3 months before Visit 1.</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
</DOC>